Clinical efficacy of anagliptin administration in type 2 diabetic patients

Clinical efficacy of anagliptin administration in type 2 diabetic patients - Clinical efficacy of anagliptin administration in type 2 diabetic patients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011071

Enrollment

Registered

2013-06-29

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly-diagnosed type 2 diabetic patients with inadequate glycemic control on diet and exercise Type 2 diabetic patients being treated with oral hypoglycemic agent,whose differences of HbA1c(measured continuously at intervals of one month or more) are less than 0.5% 1)HbA1c:more than 6.0% less than 10.0% 2)Age:more than 20 years(at the time of informed consent date) 3)No restriction on gender 4)Ability to provide written informed consent for this study

Exclusion criteria

Exclusion criteria: Out of above criteria

Design outcomes

Primary

Measure	Time frame
Glycemic control,fat,renal function and heart function after treatment with anagliptin.	—

Countries

Japan

Contacts

Public ContactSetsuya Okubo

Kuwana East Medical Center Department of Cardiology

0594-22-1211

Outcome results